Aquestive Q3 2026 slides show Anaphylm progress despite revenue miss

Aquestive Therapeutics reported Q3 2026 revenue of $7.5M, down 40.6% YoY and missing estimates. The company highlighted progress on Anaphylm, with FDA approval expected by March 2027. Cash reserves declined to $90.3M, but management expects year-end cash to exceed $70M. Shares rose 0.77% post-earnings.

Original reporting
Published Nov 4, 2026, 3:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AQST
Bearish
high confidence
Mentioned
$AQST
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AQSTBearishLow
01

Why it matters

The earnings miss highlights execution risk, while the FDA resubmission and PDUFA date provide a near‑term catalyst that could drive volatility.

02

Market read

Primary micro‑cap biotech news; relevance limited to specialty pharma investors.

03

What to watch

Cash runway remains strong above $70M and non‑dilutive financing reduces dilution risk.

Relevance 6/10Novelty 7/10Timing: after-hours reaction today

Background

Aquestive Therapeutics is a micro‑cap biotech focused on novel epinephrine delivery. The company recently out‑licensed Libervant to Eton Pharmaceuticals for $10M upfront.

Company-level read

Ticker impact

$AQSTBearishHigh confidence
Context

Q3 2026 earnings miss (revenue down 40.6% YoY) and regulatory update on Anaphylm with a PDUFA target of March 16, 2027.

Expected impact

likely modest pressure as investors price in the revenue miss, tempered by regulatory progress support

Evidence & confidence

Revenue fell sharply and missed consensus, driving short-term sell pressure; however, the resubmitted NDA and set PDUFA date are positive signals for future upside.

Market effects

Biotech sector may see modest uplift from a late-stage FDA filing, but overall impact limited to niche allergy therapeutics.

US biotech investors may adjust exposure; no broader regional effect.

Limited to investors tracking small-cap pharma pipelines.

Counterpoint

The regulatory milestone could outweigh the earnings miss, presenting a buying opportunity on dip.

Key entities

  • Dan Barber

    CEO of Aquestive Therapeutics, quoted on regulatory progress.

  • Eton Pharmaceuticals

    Recipient of out‑licensing deal for Libervant.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.